Tobira Therapeutics reverse merges with Regado Biosciences
Regado Biosciences Inc., a public anti-thrombotics company, and private biotech Tobira Therapeutics Inc. (hepatic and infectious diseases) reverse merged; the resulting entity will carry the Tobira name, be led by Tobira's CEO Laurent Fischer, MD, and be owned 68% by Tobira's existing stockholders (with Regado holding the rest). Regado will nominate three representatives to the board.
- Antisense, Oligonucleotides
- Large Molecule
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.